.Pharmacolibrary.Drugs.N_NervousSystem.N04B_DopaminergicAgents.N04BX04_Opicapone.Opicapone

Information

Opicapone is a selective and reversible catechol-O-methyltransferase (COMT) inhibitor indicated as adjunctive therapy to levodopa/carbidopa in adult patients with Parkinson’s disease with end-of-dose motor fluctuations. It is orally administered and approved in several countries for this purpose.

Pharmacokinetics

Healthy adult volunteers, following single oral administration of opicapone 50 mg.

References

1. Scott, LJ (2016). Opicapone: A Review in Parkinson's Disease. Drugs 76(13) 1293–1300. DOI:10.1007/s40265-016-0623-y PUBMED:https://pubmed.ncbi.nlm.nih.gov/27498199

2. Cabreira, V, et al., & Massano, J (2019). Contemporary Options for the Management of Motor Complications in Parkinson's Disease: Updated Clinical Review. Drugs 79(6) 593–608. DOI:10.1007/s40265-019-01098-w PUBMED:https://pubmed.ncbi.nlm.nih.gov/30905034

3. Nomoto, M, et al., & Hattori, N (2021). Pharmacokinetic Comparison of Capsule and Tablet Formulations of Opicapone in Healthy Japanese Subjects: Phase 1 Study. Clinical pharmacology in drug development 10(2) 173–179. DOI:10.1002/cpdd.802 PUBMED:https://pubmed.ncbi.nlm.nih.gov/32459885

Revisions

• 06/2025 initial generated model